N-(3-(2-(2-aminopyrimidin-5-yl)-4-morpholinopyrido[3,2-d]pyrimidin-7-yl)phenyl)-4-fluorobenzenesulfonamide | 1557079-76-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N-(3-(2-(2-aminopyrimidin-5-yl)-4-morpholinopyrido[3,2-d]pyrimidin-7-yl)phenyl)-4-fluorobenzenesulfonamide
• 英文别名: N-[3-[2-(2-aminopyrimidin-5-yl)-4-morpholin-4-ylpyrido[3,2-d]pyrimidin-7-yl]phenyl]-4-fluorobenzenesulfonamide
• CAS: 1557079-76-1
• 化学式: C₂₇H₂₃FN₈O₃S
• 分子量: 558.596
• InChiKey: RCOSFHZUQDHBNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.51
• 重原子数：
  40.0
• 可旋转键数：
  6.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  149.11
• 氢给体数：
  2.0
• 氢受体数：
  10.0

反应信息

• 作为产物：
  描述：

  3-(2-chloro-4-morpholinopyrido[3,2-d]pyrimidin-7-yl)aniline 在 吡啶 、 potassium phosphate 、 四(三苯基膦)钯 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 N-(3-(2-(2-aminopyrimidin-5-yl)-4-morpholinopyrido[3,2-d]pyrimidin-7-yl)phenyl)-4-fluorobenzenesulfonamide
  参考文献：
  名称：

  Substituted Amino-Pyrimidine Derivatives

  摘要：

  本申请提供了新型的取代喹唑啉和吡啶并嘧啶化合物及其药用可接受的盐、前药和溶剂化合物。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物在共同调节PI3K和/或mTOR活性方面是有用的。通过这样做，这些化合物在治疗与PI3K/AKT/mTOR途径失调相关的疾病方面是有效的。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  US20140038952A1

文献信息

• Substituted amino-pyrimidine derivatives
  申请人：Asana Biosciences, LLC

  公开号：US09145411B2

  公开（公告）日：2015-09-29

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐、前药和溶剂。还提供了制备这些化合物的方法。通过向患者投予一种或多种化合物的治疗有效量，这些化合物有助于共同调节PI3K和/或mTOR活性。通过这样做，这些化合物对治疗与PI3K/AKT/mTOR通路失调相关的疾病非常有效。有利的是，这些化合物表现为双重PI3K/mTOR抑制剂。这些化合物可以治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一种实施方式中，该疾病是癌症。
• SUBSTITUTED AMINO-PYRIMIDINE DERIVATIVES
  申请人：Asana Biosciences, LLC

  公开号：US20160016952A1

  公开（公告）日：2016-01-21

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新型取代喹唑啉和吡啶并嘧啶化合物及其药学上可接受的盐，前药和溶剂。同时还提供了制备这些化合物的方法。这些化合物通过向患者投予一种或多种化合物的治疗有效量来共同调节PI3K和/或mTOR活性。通过这样做，这些化合物在治疗与PI3K/AKT/mTOR途径失调相关的疾病方面具有有效性。有利的是，这些化合物作为双重PI3K/mTOR抑制剂发挥作用。这些化合物可用于治疗多种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一种实施例中，该疾病是癌症。
• US9145411B2
  申请人：——

  公开号：US9145411B2

  公开（公告）日：2015-09-29
• [EN] SUBSTITUTED 5 - (QUINAZOLIN - 2 - YL) PYRIMIDIN- 2 -AMINE DERIVATIVES USEFUL AS PI3K/MTOR INHIBITORS FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS 5-(QUINAZOLIN-2-YL)PYRIMIDIN-2-AMINES SUBSTITUÉS UTILES COMME INHIBITEURS DE PI3K/MTOR POUR LE TRAITEMENT DU CANCER
  申请人：ENDO PHARMACEUTICALS INC

  公开号：WO2014022728A1

  公开（公告）日：2014-02-06

  The present application provides novel substituted quinazoline and pyrido-pyrimidine compounds of formula (I) and pharmaceutically acceptable salts, prodrugs, and solvates thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.